Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

DCEP regimen

A regimen consisting of dexamethasone, cyclophosphamide, etoposide, and cisplatin that may be used as a salvage regimen for relapsed and/or refractory plasma cell myeloma and/or as a mobilization regimen, followed by granulocyte colony-stimulating factor (G-CSF), for peripheral blood stem cell (PBSC) collection in plasma cell myeloma.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:dexamethasone-cyclophosphamide-etoposide-cisplatin
dexamethasone-Cytoxan-Vepesid-Platinol
dexamethasone/cyclophosphamide/etoposide/cisplatin
dexamethasone/cyclophosphamide/etoposide/cisplatin regimen
Abbreviation:DCEP
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search